CRS Issue Briefs by Schacht, Wendy H. & Thomas, John R.
Congressional Research Service ˜ The Library of Congress
CRS Issue Brief for Congress





Updated June 30, 2003
Wendy H. Schacht and John R. Thomas





General Provisions of the Law
Selected Patent-Related Issues
Federal Trade Commission Report
FDA Rule Change
Proposed Legislative Changes: 108th Congress
S. 1, Title VII/S. 1225: Greater Access to Affordable Pharmaceuticals Act/H.R. 2491
S. 54: Greater Access to Affordable Pharmaceuticals Act/S. 7 (Title II): Prescription
Drug Benefit and Cost Containment Act
H.R. 1, Title XI: Access to Affordable Pharmaceuticals
H.R. 1199: Medicare Rx Drug Benefit and Discount Act of 2003
H.R. 828: Pharmaceutical Fiscal Accountability Act of 2003




Congressional Research Service ˜ The Library of Congress
The Hatch-Waxman Act: Proposed Legislative Changes
Affecting Pharmaceutical Patents
SUMMARY
Congressional interest in the cost of
pharmaceuticals, particularly for the elderly,
has focused attention on several areas where
the federal government has programs and
policies associated with the development and
accessibility of drugs in the marketplace. One
of the most prominent legislative initiatives in
this area is P.L. 98-417, the Drug Price Com-
petition and Patent Term Restoration Act of
1984 (commonly known as the Hatch-Waxm-
an Act) which made several significant
changes to the patent laws as they apply to
pharmaceutical products. These changes
include provisions for extending the term of a
patent to reflect regulatory delays encountered
in obtaining marketing approval by the Food
and Drug Administration (FDA); a statutory
exemption from patent infringement for activ-
ities associated with regulatory marketing
approval; establishment of mechanisms to
challenge the validity of a pharmaceutical
patent; and a reward for disputing the validity,
enforceability, or infringement of a patented
and approved drug. The Hatch-Waxman Act
also provides the FDA with certain authorities
to offer periods of marketing exclusivity for a
pharmaceutical independent of the rights
conferred by patents.
The provisions contained in the Act were
designed to balance the need for innovative
new pharmaceuticals and the availability of
less expensive generic drugs. Over the 18
years since passage of the Hatch-Waxman
Act, questions have been raised as to whether
or not implementation of certain portions of
the law has led to unintended consequences
that have affected this balance.
Some argue that brand name companies
and/or generic firms have exploited provisions
of the Act to prevent the timely introduction
of lower cost drugs. Several bills have been
introduced in the past several years, as well as
in the 108th Congress, that would make
changes to the Hatch-Waxman Act to address
issues of pharmaceutical patents listed in the
Orange Book maintained by the Food and
Drug Administration, patent challenges by
generic firms, and the award of market exclu-
sivity, among other things. Other observers
assert that no such pattern of abuse is evident
and that while a few isolated cases of “misin-
terpretation” of the law have arisen, these can
be addressed through existing procedures.
Proponents of the current law maintain that





P.L. 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984
(commonly known as the Hatch-Waxman Act), made several significant changes to the
patent laws designed to encourage innovation in the pharmaceutical industry while
facilitating the speedy introduction of lower-cost generic drugs. However, over the 18 years
since passage of the Hatch-Waxman Act, concerns have arisen as to whether or not
implementation of certain portions of the law has led to unintended consequences that have
affected attainment of the legislation’s original goals. Some argue that brand name
companies and/or generic firms have exploited provisions of the Act to prevent the timely
introduction of lower cost drugs. Other Members of Congress and additional experts
maintain that no pattern of abuse exists and that while a few isolated cases of
“misinterpretation” of the law have arisen, these can be addressed through existing
procedures and legislative changes are not necessary. In the 108th Congress, several bills
have been introduced that would amend the Hatch-Waxman Act. S. 1225, the Greater
Access to Affordable Pharmaceuticals Act, has been incorporated as an amendment into S.
1 (Title VII), the Prescription Drug and Medicare Improvement Act passed by the Senate on
June 27, 2003. In the House, Title XI of H.R. 1, the Medicare Prescription Drug and
Modernization Act of 2003, also addresses issues of pharmaceutical patents listed in the
Orange Book, patent challenges by generic firms, and the award of market exclusivity,
among other things. Additional bills introduced in the current Congress that would make
changes to the Hatch-Waxman Act include H.R. 2491 (identical to S. 1225), S. 54, Title II
of S. 7, H.R. 828, Title II of H.R. 1199, and H.R. 1733.
BACKGROUND AND ANALYSIS
P.L. 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984
(commonly known as the Hatch-Waxman Act), made several significant changes to the
patent laws designed to encourage innovation in the pharmaceutical industry while
facilitating the speedy introduction of lower-cost generic drugs. These changes include
provisions for extending the term of a patent to reflect regulatory delays encountered in
obtaining marketing approval by the Food and Drug Administration (FDA); a statutory
exemption from patent infringement for activities associated with regulatory marketing
approval; establishment of mechanisms to challenge the validity of a pharmaceutical patent;
and a reward for disputing the validity, enforceability, or infringement of a patented and
approved drug. The Hatch-Waxman Act also provides the FDA with certain authorities to
offer periods of marketing exclusivity for a pharmaceutical independent of the rights
conferred by patents. The statute does not apply to antibiotic drugs. (For a detailed
discussion of the law and its implementation see CRS Report RL30756, Patent Law and Its
Application to the Pharmaceutical Industry: An Examination of the Drug Price Competition
and Patent Term Restoration Act of 1984, by Wendy H. Schacht and John R. Thomas.)
Manyexperts agree that the Act has had a significant effect on the availability of generic
substitutes for brand name drugs. Generics generally are rapidly available after patent
expiration and at lower prices. Concurrently, given the increasing investment in research and
development (R&D) and the gains in research intensity of the pharmaceutical industry, it
appears that the 1984 Act has not deterred the search for and the development of new drugs.
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However, over the 18 years since passage of the Hatch-Waxman Act, concerns have
been expressed as to whether or not implementation of certain portions of the law has led to
unintended consequences that have affected attainment of the legislation’s original goals.
Some argue that a pattern of “abuse” has been associated with the provisions of the Act and
that changes should be made to prevent such actions. Among the issues raised are actions
associated with pharmaceutical patents listed in the Orange Book, patent challenges by
generic firms, and the award of market exclusivity.
Others claim that no such pattern exists and that while a few isolated cases of
“misinterpretation” of the law have arisen, these can be addressed through existing
procedures and legislative changes are not necessary. To support this position, proponents
of the current law point out that 94% of the 8,259 generic applications filed with the FDA
raised no patent-related issues. Generic challenges to brand name pharmaceuticals have
resulted in only 58 court decisions involving 47 patents. In addition, while the Federal Trade
Commission (FTC) may be looking at several cases, to date 3 cases have resulted in consent
agreements between the parties and the government. (For a detailed discussion of the issues
raised see CRS Report RL31379, The “Hatch-Waxman” Act: Selected Patent-Related Issues,
by Wendy H. Schacht and John R. Thomas.)
General Provisions of the Law
The 1984 Hatch-Waxman Act modified the 1952 Patent Act by creating a statutory
exemption from certain claims of patent infringement. Generic manufacturers may
commence work on a generic version of an approved brand name drug any time during the
life of the patent, so long as that work furthers compliance with FDA regulations.
Although the 1984 Act provides a safe harbor from patent infringement, it also requires
would-be manufacturers of generic drugs to engage in a specialized certification procedure.
The core feature of this process is that a request for FDA marketing approval is treated as an
“artificial” act of patent infringement. This feature was intended to allow judicial resolution
of the validity, enforceability and infringement of patent rights afforded by the U.S. Patent
and Trademark Office (USPTO).
Under PL 98-417, each holder of an approved new drug application (NDA) must list
pertinent patents it believes would be infringed if a generic drug were marketed before the
expiration of these patents. The FDA maintains this list of patents in its publication,
Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as
the “Orange Book.”
A generic firm must certify its intentions with regard to each patent associated with the
generic drug it seeks to market. Four possibilities exist under the 1984 Act: (1) that patent
information on the drug has not been filed; (2) that the patent has already expired; (3) the
date on which the patent will expire; or (4) that the patent is invalid or will not be infringed
by the manufacture, use or sale of the drug for which the ANDA is submitted.
These certifications are respectively termed paragraph I, II, III, and IV certifications.
An “abbreviated new drug application” (ANDA) certified under paragraphs I or II is
approved immediately after meeting all applicable regulatory and scientific requirements.
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An ANDA certified under paragraph III must, even after meeting pertinent regulatory and
scientific requirements, wait for approval until the drug’s listed patent expires.
An ANDA applicant filing a paragraph IV certification must notify the proprietor of the
patent. The patent holder may bring a patent infringement suit within 45 days of receiving
such notification. If the patent owner timely brings a patent infringement charge against the
ANDA applicant, then the FDA must suspend approval of the ANDA until: (1) the date of
the court’s decision that the listed drug’s patent is either invalid or not infringed; (2) the date
the listed drug’s patent expires, if the court finds the listed drug’s patent infringed; or (3)
subject to modification by the court, the date that is 30 months from the date the owner of
the listed drug’s patent received notice of the filing of a Paragraph IV certification.
Once the brand name company indicates an intent to bring a patent infringement suit
against the generic company as a result of the paragraph IV filing, the FDA is prohibited
from approving the drug in question for 30 months or until such time that the patent is found
to be invalid or not infringed. If, prior to the expiration of 30 months, the court holds that
the patent is invalid or would not be infringed, then the FDA will approve the ANDA when
that decision occurs. Conversely, if the court holds the patent is not invalid and would be
infringed by the product proposed in the ANDA prior to the expiration of 30 months, then
the FDA will not approve the ANDA until the patent expires.
The first generic applicant to file a paragraph IV certification is awarded a 180-day
market exclusivity period by the FDA. The 180-day market exclusivity period ordinarily
begins on the earliest of two dates: (1) the day the drug is first commercially marketed; or (2)
the day a court decision holds that the patent which is the subject of the certification is
invalid or not infringed. The interpretation of a “court decision” includes the decision of a
U.S. district court. A successful defense of a patent infringement suit is not necessary to
obtain this exclusivity period.
Selected Patent-Related Issues
The Hatch-Waxman Act requires that when a company submits a new drug application
to the Food and Drug Administration for approval, patent information associated with that
pharmaceutical be listed in the “Orange Book,” an FDA publication. This document provides
generic manufacturers with an accessible list of approved drugs that are potentially eligible
for abbreviated new drug applications. Responsibility for maintaining the integrity of the
Orange Book is an issue. The U.S. Patent and Trademark Office issues patents on
pharmaceuticals based upon utility, novelty, and non-obviousness. The FDA provides
market approval for drugs based on efficacy and safety. In some cases, certain generic
pharmaceutical companies have taken the position that a specific listing is inappropriate.
They maintain that subsidiary patents have been added to the Orange Book that do not relate
to the patented drug’s active ingredient but still delay generic competition. However, the
patent system has long allowed improvement patents so long as a sufficient inventive
advance exists.
The role of the FDA in adjudicating Orange Book listing disagreements is limited. If
a generic pharmaceutical company disputes the accuracy of an Orange Book listing, that
enterprise must present the grounds for disagreement to the FDA in writing. The FDA will
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then request that the NDA holder confirm the propriety of the listing. Unless the NDA
holder withdraws or amends the listing, the FDA will not alter the patent information in the
Orange Book.
Under the Hatch-Waxman Act, Orange Book listing issues typically are resolved once
the patentee files a patent infringement suit against the ANDA applicant. In other words, the
1984 Act expressly allows the patentee to sue the ANDA applicant for patent infringement.
No other avenue for resolution of Orange Book listings is provided in the 1984 Act.
The law also created a statutory exemption from certain claims of patent infringement
associated with submitting a request to the FDA for marketing approval for a generic version
of a patented pharmaceutical. Several incentives are provided to generic firms to challenge
the validity of existing patents through a paragraph IV filing including the 180-day market
exclusivity period for the first generic company to make, but not necessarily win, the
challenge. Implementation of this provision has led to concerns by some in the community.
Originally, FDA regulations required that a generic firm filing an ANDA had to be sued for
patent infringement and win in court in order to receive approval for market exclusivity.
However, in response to a court decision in Mova Pharmaceutical Corp. v. Shalala, FDA
guidelines were changed to eliminate the necessity for a “successful defense” by a generic
manufacturer against claims of patent infringement prior to receiving the 180-day market
exclusivity.
Critics argue that these provisions encourage the filing of “sham” paragraph IV
certifications as generic companies attempt to obtain the first-to-file position and then work
out a “settlement” with the brand name firm that delays introduction of a generic version of
the drug. Others maintain that settlements do not necessarily interfere with the timely
marketing of generic drugs and are less expensive than court cases that typically take longer
than 30 months and are extremely costly.
Once a paragraph IV filing has been made and the patent owner declares the intention
to sue for patent infringement, the FDA is prohibited from considering the generic product
for 30 months or until the patent is found invalid or not infringed. An automatic 30-month
injunction differs from typical infringement cases not involving pharmaceuticals.
Commonly, the company suing for infringement places a bond to cover their competitor’s
market losses should the patent be found invalid or not infringed. If the patent owner
prevails, the infringer is required to pay for lost income and may be required to pay treble
damages if the infringement was willful. The patent owner may also have the offending
product taken off the market. However, given the circumstances surrounding
pharmaceuticals, it may be unlikely that a drug, once available for sale and in individual
medicine cabinets, would be removed. In addition, given the value of certain
pharmaceuticals on the market, it may be impossible for the brand name firm to recoup its
monetary loses from generic firms with significantly fewer capital resources.
Concerns also have been raised by some critics as to commencement of the 180-day
market exclusivity period. The Hatch-Waxman Act triggers the generic exclusivity in one
of two ways: either when the generic manufacturer commences commercial marketing of its
drug, or when a court decision finds the NDA holder’s patent invalid or not infringed. With
regard to the latter provision, the FDA interpreted the law as requiring a decision of the
United States Court of Appeals for the Federal Circuit to commence the exclusivity period.
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According to the FDA, ANDA applicants that prevailed at the district court level might wish
to delay marketing their generic drug until the patent infringement litigation was more
conclusively resolved on appeal. The FDA thus hoped to eliminate what it perceived to be
a difficult choice for generic applicants: either launch a generic drug while the litigation was
still pending on appeal, thereby risking infringement liability if the district court’s opinion
was overturned by the Court of Appeals or wait until the appeal was decided, which almost
certainly meant that the 180-day exclusivity period would have elapsed.
However, the United States District Court for the District Court of Columbia held that
the FDA’s interpretation of the phrase “a decision of the court” was erroneous. According
to Judge Roberts, the correct interpretation of that phrase included decisions of a U.S. district
court. Judge Roberts further reasoned that nothing prevented the first ANDA applicant from
utilizing the 180-day period if it concluded that the risk of reversal by the Court of Appeals
was low; that the FDA interpretation prolonged the period at which drug prices remained at
inflated levels; and that exclusivity periods were valuable commodities that could be traded
to, among other parties, the NDA holder.
Federal Trade Commission Report
According to the Food and Drug Administration, between 1984 (when the Hatch-
Waxman Act passed) and the end of 2000, 8,019 ANDAs were filed. No patent-related
issues were raised in 7,536 (or 94%) of these abbreviated new drug applications. In a July
2002 report titled, Generic Drug Entry Prior to Patent Expiration, the Federal Trade
Commission studied those ANDAs filed between January 1, 1992 and December 31, 2000
containing a paragraph IV certification challenging patents associated with the brand name
drug. During this time period, 104 NDAs were the subject of paragraph IV certifications.
The FTC found that the patent owner sued the first generic applicant in 75 instances.
Of the patent challenges brought to court and decided as of June 1, 2002, the patent was
found to be invalid in 11 cases and the patents were found not to be infringed in 14 cases.
Twenty suits resulted in a settlement between the brand name company and the generic firm.
The analysis by the FTC indicated that the first 30-month stay expired before a district court
decision was reached in 22 of the 75 cases that were litigated or are currently in the process
of litigation between the brand name firm and the first generic applicant.
In approximately 85% of the cases where the patent owner sued the first ANDA
applicant, the brand name company also sued the second generic applicant. To date, 40 drug
products were the subject of court cases. In 29 of these suits, the generic applicant won
while in 11 others the decision favored the brand name firm.
During the time period studied, in 8 instances additional patents were listed in the
Orange Book after an initial ANDA filing. Six of these cases occurred since 1998. Approval
by the FDA was delayed an additional 4 to 40 months. Four cases have been resolved in
court to date and the patents were found to be either invalid or not infringed.
The FTC report claims that FDA approval of ANDA applications without a paragraph
IV certification took an average 25 months, 15 days. The time between a “complaint” and
a district court decision on a patent infringement challenge took an average 25 months, 13
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days. The time between a “complaint” and an appellate court decision was an average 37
months, 20 days. Most generic companies have waited for at least a district court decision
prior to entering the market. Three-quarters of the patent cases resolved to date have favored
the generic firm.
Since 1998, 31 generic products have received an 180-day market exclusivity provided
by the FDA. Between 1992 and 1998, no 180-day market exclusivity was granted. The FTC
found that 14 of the 20 settlements reached between the brand name companies and generic
firms had the potential to “park” the first generic applicant’s use of market exclusivity and
thereby delay entry of additional generic versions of the product.
Utilizing the results of this study, the FTC made the following recommendations (with
accompanying rationale) for changes in existing law:
1. Allow only one automatic 30-month stay per drug product per ANDA. Currently,
according to the study, it appears that one stay associated with patents filed prior to the initial
ANDA does not delay generic entry beyond the time needed for FDA approval of the filing.
However, there appear to be problems associated with later-listed patents. The FTC
identified questions as to whether or not later-listed patents actually meet the listing
requirements to be included in the Orange Book, noting that the only way to challenge these
listings is through a patent infringement suit.
2. Enact legislation to require brand name companies and first-to-file generic firms to
provide the FTC with copies of certain agreements between the parties. Antitrust scrutiny
should be permitted to insure that such agreements do not delay the first generic’s use of the
180-day market exclusivity rights.
The FTC study also recommends that: the term “commercial marketing” be clarified
to include instances where the first generic firm markets the brand name drug; the meaning
of a “court decision” be codified to include any court decision on the same patent being
litigated by the first generic filer; and any dismissal of a declaratory judgment action for lack
of a case or controversy should be considered a “court decision” necessary to trigger the 180-
day market exclusivity period.
FDA Rule Change
On June 12, 2003, the Food and Drug Administration announced new rules associated
with the 30-month stay and the requirements for listing patents in the Orange Book.
Originally published as a proposal in the October 24, 2002 Federal Register, the new
regulations would allow only one 30-month stay in the approval date of each ANDA or
505(b)(2) application. The agency will now prohibit the Orange Book listing of patents for
drug packaging, drug metabolites, and intermediate forms of a drug. Process patents are not
to be listed, although product-by-process patent information is required when the product
claimed is novel. NDA holders are obligated to provide additional patent-related information
upon listing in the Orange Book and sign as to the veracity of the information under threat
of criminal charges for false statements. These changes are similar to those suggested by
the Federal Trade Commission and will be effective on August 18, 2003. However, some
experts contend that the FDA does not have the authority to alter application of the Hatch-
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Waxman Act through the regulatory process without related legislative changes. They
predict that the FDA actions will be challenged in court.
Proposed Legislative Changes: 108th Congress
Many Members of Congress and other experts maintain that the Hatch-Waxman Act
continues to successfully balance the need for innovative new pharmaceuticals and the
availability of less expensive generic drugs. They note that since passage of the law, the
amount of investment bypharmaceutical companies in biomedical research and development
has increased while the number of lower cost generic drugs has expanded significantly.
Further, those who oppose changes to the Act argue that existing procedures and current law
is sufficient to address any “misinterpretation” or “misuse” of the legislation.
However, several bills have been introduced in the 108th Congress that would make
changes to the Hatch-Waxman Act. The bills are discussed below:
S. 1, Title VII/S. 1225: Greater Access to Affordable
Pharmaceuticals Act/H.R. 2491
S. 1225, incorporated as an amendment to S. 1 (Title VII), the Prescription Drug and
Medicare Improvements Act passed by the Senate on June 27, 2003, provides only one 30-
month stay for patents listed in the Orange Book at least one day prior to the filing of a
paragraph IV ANDA. Related patents listed after the filing of an ANDA do not trigger an
additional 30-month stay unless that subsequently issued patent is challenged in a separate
proceeding. The ANDA applicant would be permitted to request a declaratory judgement
from the courts that the patent is unenforceable, invalid, or not infringed if the patent owner
fails to bring an infringement suit within 45 days of the filing of a paragraph IV certification.
In addition, under this bill, the ANDA applicant may file a counter claim to require the patent
holder to change or delete information in the Orange Book if the patent owner files an
infringement suit.
The proposed legislation amends the Hatch-Waxman Act to mandate that the 180-day
marketing exclusivity period begins on the date of the final decision of a court from which
no appeal can, or has been taken, or the date of a settlement order or consent decree. The
first ANDA applicant will be required to forfeit the 180-day exclusivity to subsequent
applicants under certain situations including the failure to market, withdrawal of the
application, change of certification from a paragraph IV to a paragraph III, failure to obtain
tentative FDA approval, failure to challenge the patent, or an FTC determination that an
agreement with a patent holder violates antitrust laws. H.R. 2491 contains similar
provisions. (To track additional prescription drug provisions that may be included in this
legislation see CRS Report RL31966, Medicare Prescription Drug and Reform Legislation,
by Jennifer O’Sullivan, et al., and CRS Report RL31503, Importing Prescription Drugs, by
Blanchard Randall IV and Donna U. Vogt.)
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S. 54: Greater Access to Affordable Pharmaceuticals Act/S. 7 (Title
II): Prescription Drug Benefit and Cost Containment Act
S. 54, as introduced in the current Congress (and passed by the Senate as S. 812 in the
107th Congress) and Title II of S. 7 would make alterations to the Hatch-Waxman Act that
distinguish between patents listed in the Orange Book at the time of FDA approval of the
NDA and those patents listed at a later date. Brand name companies must file and list all
existing patents within 30 days of NDA approval. If a paragraph IV certification is filed by
a generic firm and the patent owner signals an intent to sue, an automatic 30-month stay will
be granted during which time the FDA is prohibited from approving the ANDA. A transition
period is provided that gives NDA holders 30 days to list all patents upon passage of the bill.
Subsequent patents awarded to the NDA holder must be listed in the Orange Book
within 30 days. If the patents are not listed in 30 days, the patent owner loses the right to sue
for infringement and the patent is no longer enforceable. If the patent holder does not sue
for infringement within 45 days, then the right to sue is forfeited. No automatic injunction
may be granted for these patents; a court must decide to grant a preliminary injunction by
balancing the following four factors: likelihood of success on the merits, irreparable harm,
public interest, and the balance of hardships. However, the court is prohibited from
considering the ability to pay damages when granting the injunction.
The ANDA applicant may commence a civil action to correct or delete the original
patents listed in the Orange Book. No damages can be awarded for patents that are removed
from the Orange Book. Listed patents are required to provide more information regarding
the type of patent than is currently mandated.
The legislation mandates that the 180-day exclusivity period begin on the date of a final
decision of a court from which no appeal can or has been taken, It further identifies situations
in which the first generic company to file a paragraph IV ANDA must forfeit the 180-day
market exclusivity. The next ANDA applicant may receive the exclusivity period. In filing
a paragraph IV certification, the generic company must be specific as to why the patent is
considered invalid or not infringed.
H.R. 1, Title XI: Access to Affordable Pharmaceuticals
Title XI of H.R. 1, as passed by the House on June 27, 2003, would eliminate the
automatic 30-month stay and would require a patent owner to obtain a preliminary injunction
preventing the FDA from considering the ANDA involved in an infringement suit. If a
patent holder does not file an infringement suit within 45 days of notification of a paragraph
IV ANDA, the ANDA applicant may request a declaratory judgement regarding the validity
of the patent. ANDA applicants are required to notify the patent owner of a certification
within 20 days. The ANDA applicant may amend the certification, but is prohibited from
listing another drug in that application.
This bill also creates situations in which the 180-day market exclusivity would be
forfeited including failure to market, withdrawal of the application, amendment of the
certification, failure to obtain approval, enters into an agreement deemed anticompetitive by
the FTC or the Attorney General, or the patents expire. No other applicant would be
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permitted the 180-day exclusivity. The exclusivity would begin on the date of an appeals
court decision, the date of settlement order or consent decree, or when a district court
decision is not appealed.
H.R. 1199: Medicare Rx Drug Benefit and Discount Act of 2003
Title II of H.R. 1199 (which addresses Medicare prescription issues) permits the 180-
day market exclusivity period to begin on the day of a court decision from which no appeal
can or has been taken. The bill establishes conditions under which the first ANDA applicant
must forfeit the 180-day exclusivity provided by the Food and Drug Administration. The
next company to file an ANDA containing a paragraph IV certification can receive the
market exclusivity period if the original firm forfeits its claims.
Provisions contained in the bill would eliminate the 30-month stay and would require
the patent owner to obtain an injunction from the courts under general equitable principles
(e.g. a strong case that the patent is valid and infringed; the likelihood that the patent owner
would suffer irreparable harm, the balance of hardships, and the public interest). In the
absence of an injunction, the FDA may approve the generic after 45 days. Further, ANDA
applicants are permitted to bring a “declaratory judgment action”against NDA holders who
have listed patents in the Orange Book. This action provides an additional mechanism to
determine the validity and infringement status of the patent in question.
Under this proposed bill, the FDA is permitted to approve generic drugs with a medical
indication that is no longer under patent, even if a patent or marketing exclusivity covers
another indication of that same drug. In these instances, the generic company may not
provide instructions on how to use the drug for uses proprietary to another. The FDA may
require that the generic drug’s label provide necessarysafety instructions or stipulate because
a particular use is exclusive to another, the drug is not labeled for a particular use.
Agreements reached between brand name companies and generic firms regarding the
sale of a generic drug that is equivalent to the drug marketed by the patent owner must be
submitted to the FDA and the Federal Trade Commission (FTC) for review within 10 days
of their completion. Parties that fail to file such agreements can be fined and imprisoned.
The FTC may engage in rulemaking to carry out this legislation. The effective date of the
provisions of this Part is 90 days afer its enactment.
H.R. 828: Pharmaceutical Fiscal Accountability Act of 2003
Section 3 of H.R. 828 permits subsequent ANDA holders to obtain FDA marketing
approval if certain conditions are not met by the original ANDA applicant.
H.R. 1733: (Title IV) Greater Access to Affordable Pharmaceuticals
Act of 2003
The provisions of H.R. 1733 are similar to S. 54 with several exceptions. This bill
would eliminate completely the 30 month stay even for those patents that were listed in the
Orange Book prior to the passage of the legislation. A preliminary injunction would be
required to prevent the approval of an ANDA by a generic firm. A brand name company
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would not loose the right to enforce a patent if it is not listed in the Orange Book within a
specified time frame or if the firm does not begin an infringement suit within 45 days as
mandated in S. 54. The bill would also permit the use of citizen petitions.
LEGISLATION
H.R. 1 (Hastert)
Medicare Prescription Drug and Modernization Act of 2003. Title XI of H.R. 1 makes
changes to the Hatch-Waxman Act. Introduced June 25, 2003; referred to the House
Committees on Energy and Commerce and Ways and Means. Passed Senate on June 27,
2003.
H.R. 828 (McCarthy, C.)
Section 3 makes changes to the Hatch-Waxman Act. Introduced February 13, 2003;
referred to the House Committee on Energy and Commerce.
H.R. 1199 (Rangel)
Medicare Rx Drug Benefit and Discount Act of 2003. Title II makes changes to the
Hatch-Waxman Act. Introduced March 24, 2003; referred to the House Committee on
Energy and Commerce.
H.R. 1733 (Crowley)
Title IV makes changes to the Hatch-Waxman Act. Introduced April 10, 2003; referred
to the House Committees on Energy and Commerce, Ways and Means, Veterans’ Affairs,
and Administration.
S. 1 (Frist)
Prescription Drug and Medicare Improvements Act. Language of S. 1225 incorporated
as an amendment which makes changes to the Hatch-Waxman Act. S. 1 introduced June 11,
2003; referred to the Senate Committee on Finance. Passed Senate, amended, on June 27,
2003.
S. 7 (Daschle)
Prescription Drug Benefit and Cost Containment Act of 2003. Title II makes changes
to the Hatch-Waxman Act. Introduced January 7, 2003; referred to the Senate Committee
on Finance.
S. 54 (Schumer/McCain)
Greater Access to Affordable Pharmaceuticals Act of 2003. Makes changes to the
Hatch-Waxman Act similar to those proposed in S. 812 as passed by the Senate in the 107th
Congress. Introduced January 7, 2003; referred to the Senate Committee on Health,
Education, Labor, and Pensions.
S. 1255 (Gregg/Schumer/McCain/Kennedy)/H.R. 2491 (Emerson)
Greater Access to Affordable Pharmaceuticals Act. Makes changes to the Hatch-
Waxman Act. S. 1255 introduced June 10, 2003; referred to the Senate Committee on
Health, Education, Labor, and Pensions. Ordered reported from Committee on June 11,
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2003. Incorporated as an amendment into S. 1, the Prescription Drug and Medicare
Improvements Act on June 19, 2003. Passed the Senate as incorporated in S. 1 on June 27,
2003. H.R. 2491 introduced June 17, 2003; referred to the House Committees on Energy and
Commerce and the Judiciary.
FOR ADDITIONAL READING
CRS Report RL30756. Patent Law and Its Application to the Pharmaceutical Industry: An
Examination of the Drug Price Competition and Patent Term Restoration Act of 1984,
by Wendy H. Schacht and John R. Thomas.
CRS Report RL31379. The “Hatch-Waxman” Act: Selected Patent-Related Issues, by
Wendy H. Schacht and John R. Thomas.
CRS Report RS21129. Pharmaceutical Patent Term Extensions: A Brief Explanation, by
Wendy H. Schacht and John R. Thomas.
CRS Report RL30913. Pharmaceutical Research and Development: A Description and
Analysis of the Process, by Richard E. Rowberg.
